Skip to main content
SpringerLink
Log in

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Clozapine has had a uniquely favorable motor system side effect profile since its initial evaluations. This has been convincingly corroborated by many double blind, single blind, and open studies treating acute and chronic psychosis. The acute extrapyramidal syndromes of dystonia, akathisia and parkinsonism infrequently occur, whereas these syndromes develop in up to 75% of patients receiving traditional neuroleptics. Tardive dyskinesia can be suppressed with higher doses of clozapine given over extended periods. However, an antipsychotic effect can be achieved in many patients at doses below the dyskinesia suppressing level. There is no established causative relationship between clozapine and tardive dyskinesia, but there is a theoretical basis that this may occur. Preliminary data suggest clozapine has mild antiparkinsonian effects as well as efficacy in controlling dopamine agonist-induced psychosis without aggravating parkinsonism. A much wider use of clozapine will further characterize the magnitude of differences compared to other neuroleptics, and identify additional indications for this special compound.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin: Untersuchung mit dem AMP-System. Pharmakopsychiatrie 4:200–211

    Google Scholar 

  • Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A (1972) Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol 27:180–190

    Google Scholar 

  • Bürki HR, Ruch W, Asper H (1975) Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacologia 41:27–33

    Google Scholar 

  • Caine E, Polinsky R, Kartzinel R, Ebert M (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317–320

    Google Scholar 

  • Carroll BJ, Curtis GC, Kokmen K (1977) Paradoxical response to dopamine agonists in tardive dyskinesia. Am J Psychiatry 134:785–789

    Google Scholar 

  • Casey DE (1987) Tardive dyskinesia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1411–1419

    Google Scholar 

  • Casey DE (1988) Affective disorders and tardive dyskinesia. L'Encephale 14:221–226

    Google Scholar 

  • Casey DE, Gerlach J (1986) Tardive dyskinesia: what is the long-term outcome? In: Casey DE, Gardos G (eds) Tardive dyskinesia and neuroleptics: from dogma to reason. Am Psychiatr Press, Washington, DC, pp 76–97

    Google Scholar 

  • Casey DE, Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York, Tokyo, pp 74–83

    Google Scholar 

  • Chiu E, Burrows G, Stevenson J (1976) Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust N Z J Psychiatry 10:343–347

    Google Scholar 

  • Chouinard G, Annable L (1976) Clozapine in the treatment of newly admitted schizophrenic patients. J Clin Pharmacol 16:289–297

    Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab F, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377–384

    Google Scholar 

  • Cole JO, Gardos G, Tarsy D (1980) Drug trials in persistent dyskinesia. In: Fann WE, Smith RC, Davis JM, Domino EF (eds) Tardive dyskinesia: research and treatment. SP Medical and Scientific Books, New York, pp 419–427

    Google Scholar 

  • Delay J, Deniker P (1957) Characteristiques neuro-physiologiques des medicaments neuroleptiques. Rapport Symposium Internationale Medicaments Psychotropies. In: Garratini S, Ghetti V (eds) Psychotropic drugs. Elsevier, Amsterdam, pp 485–501

    Google Scholar 

  • DeMaio D (1972) Clozapine, a novel major tranquilizer. Arzneimittelforschung 22:919–923

    Google Scholar 

  • Doepp S, Buddeberg C (1975) Extrapyramidale Symptone unter Clozapin. Nervenarzt 46:589–590

    Google Scholar 

  • Ekblom B, Haggstrom JE (1974) Clozapine compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16:945–957

    Google Scholar 

  • Fischer-Cornelssen KA, Ferner UJ (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychol Bull 12:34–39

    Google Scholar 

  • Gerbino L, Shopsin B, Collora M (1980) Clozapine in the treatment of tardive dyskinesia: an interim report. In: Fann WE, Smith RC, Davis JM, Domino EF (eds) Tardive dyskinesia: Research and treatment. SP Medical and Scientific Books, New York, pp 475–489

    Google Scholar 

  • Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77:369–378

    Google Scholar 

  • Gerlach J, Simmelsgaard H (1978) Tardive dyskinesia during and following treatment with haloperidol plus biperiden, thioridazine, and clozapine. Psychopharmacology 59:105–112

    Google Scholar 

  • Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424

    Google Scholar 

  • Gerlach J, Thorsen K, Fog R (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40:341–350

    Google Scholar 

  • Gross H, Hackl H, Kaltenbaeck E (1970) Results of double-blind study of clozapine and thioridazine. VII CINP Congress, Prague

  • Hemphill RE, Pascoe FD Zabow T (1975) An investigation of clozapine in the treatment of acute and chronic schizophrenic and gross behaviour disorders. S Afr Med J 49:2121–2125

    Google Scholar 

  • Hyttel J, Larsen JJ, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlanch J (eds) Dyskinesia research and treatment. Psychopharmacology Supplementum 2, Springer, Berlin Heidelberg New York, pp 9–18

    Google Scholar 

  • Itoh H, Miura S, Yagi G, Sakurai S, Ohtsuka N (1977) Some methodological considerations for the clinical evaluation of neuroleptics-comparative effects of clozapine and haloperidol on schizophrenics. Folia Psychiatr Neurol Jpn 31:17–24

    Google Scholar 

  • Jenner P, Marsden CD (1983) Neuroleptics and tardive dyskinesia. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral, and clinical perspectives. Raven Press, New York, pp 223–253

    Google Scholar 

  • Juul Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176–185

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Keepers G, Casey DE (1987) Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 7:342–344

    Google Scholar 

  • Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117

    Google Scholar 

  • Kirkegaard A, Hammershoj E, Ostergard P (1982) Evaluation of side effects due to clozapine in long-term treatment of psychosis. Arzneimittelforschung 32:465–468

    Google Scholar 

  • Kuha S, Miettinen E (1986) Long-term effect of clozapine in schizophrenia: a retrospective study of 108 chronic schizophrenics treated with clozapine for up 7 years. Nord Psykiatr Tidsshrl 40:225–230

    Google Scholar 

  • Matz R, Rick W, Oh D, Thompson H, Gershon S (1974) Clozapine — a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res 16:687–695

    Google Scholar 

  • Meltzer HY, Luchins DJ (1984) Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 4:286–287

    Google Scholar 

  • Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73:295–297

    Google Scholar 

  • Panteleeva MY, Tsutsul Kovskaya MY, Belyaev BS, Minsker EI (1987) Clozapine in the treatment of schizophrenic patients: an international multicenter trial. Clin Ther 10(1):57–68

    Google Scholar 

  • Pope HG, Cole JO, Choras PT, Fulwiler CE (1986) Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174:493–495

    Google Scholar 

  • Sayers A, Bürki H, Ruch W, Asper H (1975) Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 41:97–104

    Google Scholar 

  • Sayers A, Bürki H, Ruch W, Asper H (1976) Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51:15–22

    Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235:60–64

    Google Scholar 

  • Shopsin B, Klein H, Aaronsom M, Collora M (1979) Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiatry 36:657–664

    Google Scholar 

  • Simpson GM, Varga E (1974) Clozapine — a new antipsychotic agent. Curr Ther Res 16:679–686

    Google Scholar 

  • Simpson G, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56:75–80

    Google Scholar 

  • Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ (1987) Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 48:263–267

    Google Scholar 

  • Stille G, Lauener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo diazepine (clozapine). Il Farmaco 26:603–625

    Google Scholar 

  • Toenniessen LM, Casey DE, McFarland BH (1985) Tardive dyskinesia in the aged. Arch Gen Psychiatry 42:278–284

    Google Scholar 

  • Thorup M, Fog R (1977) Clozapine treatment of schizophrenic patients; Plasma concentration and coagulation factors. Acta Psychiatr Scand 55:123–126

    Google Scholar 

  • Van Praag HM, Korf J, Dols LCW (1976) Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. Br J Psychiatry 129:547–555

    Google Scholar 

  • Van Putten T, Mutalipassi LR Malkin MD (1974) Phenothiazine-induced decompensation. Arch Gen Psychiatry 30:102–105

    Google Scholar 

  • White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatry Service (116A), VA Medical Center, 97207, Portland, OR, USA

    Daniel E. Casey (Chief, Professor of Psychiatry, Associate Professor of Neurology)

  2. Oregon Health Sciences University, Portland, Ofegon, USA

    Daniel E. Casey (Chief, Professor of Psychiatry, Associate Professor of Neurology)

Authors
  1. Daniel E. Casey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casey, D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 (Suppl 1), S47–S53 (1989). https://doi.org/10.1007/BF00442559

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00442559

Key words

Search

Navigation